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Open acHepatocyte senescence explains conjugated bilirubinaemia
in chronic liver failureTo the Editor:
Conjugated bilirubinaemia in patients with chronic liver disease
(CLD) reﬂects hepatic decompensation and a poor prognosis [1].
The pathophysiology that underlies conjugated bilirubinaemia
in hepatic decompensation is poorly understood. There is no
demonstrable ﬂaw in processing unconjugated bilirubin and a
more likely explanation is altered hepatocyte handling of conju-
gated bilirubin.
Hepatocyte senescence is present across diverse aetiologies
and as many as 80% of hepatocytes show the senescent pheno-
type in advanced liver disease [2]. Metabolic activity is altered
when a cell becomes senescent and one potential consequence
is an alteration of conjugated bilirubin transport in senescent
hepatocytes, which accumulate in advanced CLD.
Serum bilirubin and hepatocyte telomere length were
measured in 70 patients within the spectrum of NAFLD. Mean
hepatocyte telomere intensity, a surrogate marker of telomere
length, was measured using quantitative ﬂuorescent in-situ
hybridization, as described [3]. There was an inverse relationship
between serum bilirubin and hepatocyte telomere length
(p = 0.04, Fig. 1). Thus, accelerated hepatocyte ageing is associ-
ated with jaundice.
Liver sections from ﬁve of those patients were double-stained
using unconjugated mouse monoclonal anti-p21 (Dako; concen-
tration 1:100, heat-induced EDTA-based antigen retrieval,
20 min) and unconjugated mouse monoclonal anti-MRP2
(Merck Millipore; concentration 1:20, heat-induced citrate-
based antigen retrieval, 20 min). MRP2 was negative in p21-
positive (senescent) hepatocytes and was only detected in
p21-negative hepatocytes (Fig. 1). Reliable immunohistochemi-
cal staining could not be achieved with available MRP3
antibodies.
An in vitro model was used to examine gene expression of
MRP2 and MRP3 in senescent hepatocytes by real-time PCR.
Cellular senescence was induced in HepG2 cells by incubation
with 0.5 mMH2O2 in culturemedium for 60 minutes, as described
[4]. Expression of MRP2 was downregulated in senescent
HepG2 cells; in contrast, expression of MRP3 was upregulated
(Fig. 1).
Hepatocytes are polarised cells; MRP2 is restricted to the
canalicular (apical) membrane, whereas MRP3 is found only in
the sinusoidal (basolateral) membrane [5]. Both MRP2 and
MRP3 are unidirectional efﬂux pumps, which transport
conjugated bilirubin into the canalicular space (bile) or the
sinusoid (blood), respectively [5]. Reduced MRP2 expression in
senescent hepatocytes in vitro and an absence of MRP2 protein
in p21-positive (senescent) hepatocytes suggest reduced conju-
gated bilirubin transport into the biliary canaliculi. Increased
MRP3 expression in senescent hepatocytes may be compen-
satory, increasing transport of conjugated bilirubin into the hep-
atic sinusoid (Fig. 1). It is, however, not clear why changes in
MRP2 and MRP3 accompany hepatocyte senescence.Journal of Hepatology 2015 vol. 63 j 525–535
cess under CC BY-NC-ND license.
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Fig. 1. Hepatocyte senescence, jaundice and bilirubin transporters. (A)
Hepatocyte telomere length was associated inversely with the serum bilirubin
level in 70 patients with non-alcohol related fatty liver disease. (B)
Immunohistochemical double-staining showed membranous MRP2 staining in
p21-negative (blue nuclei; normal) hepatocytes and a lack of MRP2 staining in
p21-positive (brown nuclei; senescent) hepatocytes. (C) MRP2 expression was
downregulated and MRP3 expression was upregulated in senescent HepG2 cells.
(D) Uptake and conjugation of unconjugated bilirubin is unaffected in senescent
hepatocytes; however, altered MRP2 and MRP3 expression in senescent hepato-
cytes leads to transport of conjugated bilirubin back into the sinusoid rather than
the biliary canaliculi.
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